Labor, Endoskopie und neue Bildgebung

Herfarth, M.

doi:10.1007/s00108-002-0686-6

Der Internist

2002

DOI: 10.1007/s00108-002-0686-6

|View full text |Cite

Labor, Endoskopie und neue Bildgebung

M. Herfarth¹

Abstract: Diagnose Wahrscheinlich Möglich Unwahrscheinlich Colitis ulcerosa 43% 26% 31% M. Crohn 41% 27% 32% Unauffällig 8% 2% 90% Nicht spezifisch 12% 18% 70% 24 histologische Präparate von Patienten mit klinisch gesicherten M. Crohn wurden 10 Pathologen geblindet vorgelegt. Die Schnitte sollten in die Diagnosegruppen Colitis ulcerosa, M. Crohn, unauffällig und nicht spezifische Entzündung nach Wahrscheinlichkeiten eingeordnet werden. (Nach [82]) M. Crohn (n=43) Colitis ulcerosa (n=37) Rezidiv Kein Rezidiv Rezidiv Kein… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

2006

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Chronisch entz�ndliche Darmerkrankungen

Herrlinger

Stange

2002

Der Internist

View full text Add to dashboard Cite

The etiology of inflammatory bowel diseases is still unknown. However, there seems to be a primary defect in mucosal barrier function resulting in a chronic inflammatory process. Both entities, Crohn's disease and ulcerative colitis show characteristic differences in clinical presentation and laboratory, radiological as well as endoscopical criteria. In some cases of the so called indeterminate colitis a clear distinction may not be possible. Therapy of inflammatory bowel disease aims for a suppression of the mucosal inflammation. Site, extent and especially the course of disease are crucial for the decision when and how to treat the patient. According to the patient's symptoms and disease history topical or systemic application of mesalazine or corticosteroids are used. In case of an intermittent course of disease treatment of the single flare should be started whereas in chronic active disease an immunosuppression with azathioprine, methotrexate or in therapy refractory cases infliximab is warranted.

show abstract

Chronisch entz�ndliche Darmerkrankungen

Herrlinger

Stange

2002

Der Internist

View full text Add to dashboard Cite

show abstract

Management of inflammatory bowel diseases in Eastern Europe

Lakatos

2006

Postgraduate Medical Journal

View full text Add to dashboard Cite

Limited data are available on the management of inflammatory bowel diseases (IBD) in East European countries. The diagnostic tools and most treatment options are also available in Eastern Europe. The diagnostic procedures commonly used became more sophisticated in the past few years, with a greater use of computed tomography/magnetic resonance imaging and serology testing; however, double contrast barium enema, enteroclysis, and endoscopy remained standard. The medical therapy and surgical strategies are also somewhat different from those applied in Western countries. In ulcerative colitis, besides mesalazine, the use of sulphasalazine is still frequent, while azathioprine is only used in a minority of patients. The use of conventional corticosteroids is common and the rate of non-colorectal cancer associated colectomies is low. In contrast, 5-aminosalicylates are still used for maintenance in Crohn's disease and azathioprine is generally less frequently given compared with Western Europe. Biological agents have also become available about five years ago, yet their use is restricted mainly to specialised centres.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Labor, Endoskopie und neue Bildgebung

Cited by 2 publications

References 17 publications

Chronisch entz�ndliche Darmerkrankungen

Chronisch entz�ndliche Darmerkrankungen

Management of inflammatory bowel diseases in Eastern Europe

Contact Info

Product

Resources

About